BRIEF COMMUNICATION: Rituximab use in systemic lupus erythematosus pneumonitis and a review of current reports

BRIEF COMMUNICATION: Rituximab use in systemic lupus erythematosus pneumonitis and a review of current reports

Rituximab is a chimeric monoclonal antibody specific for human CD20 that causes selective transient depletion of the CD20 super(+) B-cell subpopulation. We report the first case of systemic lupus erythematosus (SLE) pneumonitis resistant to conventional treatments that responded well to rituximab an...

Full description

Saved in:
Bibliographic Details
Published in:Internal medicine journal Vol. 36; no. 4; pp. 260 - 262
Main Authors: Lim, S W, Gillis, D, Smith, W, Hissaria, P, Greville, H, Peh, CA
Format: Journal Article
Language:English
Published: 01-04-2006
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Rituximab is a chimeric monoclonal antibody specific for human CD20 that causes selective transient depletion of the CD20 super(+) B-cell subpopulation. We report the first case of systemic lupus erythematosus (SLE) pneumonitis resistant to conventional treatments that responded well to rituximab and review current reports on the use of rituximab in SLE.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1444-0903
1445-5994
DOI:10.1111/j.1445-5994.2006.01055.x